Venture
Scorpion Therapeutics, Inc.
Latest Form D 2024-07-16- CIK 1811858
- State MA
- Biotechnology
- 3 Form D offerings since 2020-05-19
- Total sold
- $297M
- across 3 offerings
- Rounds
- 3
- Form D offerings since 2020-05-19
- Latest round
- $126M
- 2024-07-16 · 021-518868
- Investors
- 38
- on the latest round
Connected
named in its Form D filingsOfferings · since 2020-05-193 Form D offeringsExemptions506(b)People · Item 3Adam Friedman + 14 moreInvestors · dashboard4 inferred investors
Scorpion Therapeutics, Inc.CIK 1811858
Round timeline
amount sold · by first filed2024-07-16 · $126M
- 2020-05-19$24.7M021-367229
- 2020-12-07$147M021-382478
- 2024-07-16$126M021-518868
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($147M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-518868 | First filed2024-07-16 | Latest2024-07-16 | Sought$150M | Sold$126M | Investors38 | Exemptions506(b) |
| 021-382478 | First filed2020-12-07 | Latest2020-12-07 | SoughtIndefinite | Sold$147M | Investors22 | Exemptions506(b) |
| 021-367229 | First filed2020-05-19 | Latest2020-05-19 | SoughtIndefinite | Sold$24.7M | Investors11 | Exemptions506(b) |
Who backs Scorpion Therapeutics, Inc. — 4 inferred investors — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2024-07-16
| Name | Relationship |
|---|---|
| Adam Friedman | RelationshipExecutive Officer, Director |
| Arjun Goyal | RelationshipDirector |
| Jean-Francois Formela | RelationshipDirector |
| Otello Stampacchia | RelationshipDirector |
| Shelley Chu | RelationshipDirector |
| Keith Flaherty | RelationshipDirector |
| Oleg Nodelman | RelationshipDirector |
| Jeffrey Albers | RelationshipDirector |
| Saurabh Saha | RelationshipDirector |
| Andrew Fedder | RelationshipExecutive Officer |
| Brian Piper | RelationshipExecutive Officer |
| Mark Chao | RelationshipExecutive Officer |
| Darrin Stuart | RelationshipExecutive Officer |
| Amanda Valentino | RelationshipExecutive Officer |
| Erica Jackson | RelationshipExecutive Officer |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- Massachusetts (MA)
- Exemptions
- Rule 506(b)
- First filed
- 2020-05-19
- Latest filing
- 2024-07-16
Who backs Scorpion Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗